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Summary
 
Mice exposed for 20 min daily to aerosolized ovalbumin (OVA) for 10 d at concentrations
from 1 to 0.01% OVA made greatly reduced immunoglobulin (Ig)-E responses to subsequent
immunogenic OVA challenges, given either intraperitoneally or by aerosol. This IgE-specific
unresponsiveness lasted for at least four months. However, these aerosol-treated mice were
primed for larger OVA-specific IgG1 and IgG2a responses. The specific reduction in IgE re-
sponses was not due to preferential induction of a T helper (Th)-1 response as aerosol OVA–
primed mice made greatly reduced Th2 and no detectable Th1 response after rechallenge in
vitro. Consistent with this, the increase in circulating eosinophils observed in control Th2-
primed mice was absent in aerosol OVA–treated animals. Interferon (IFN)-
 
g
 
 was not required
for this unresponsiveness, as IFN-
 
g
 
 knockout mice and anti–IFN-
 
g
 
 antibody-treated wild-type
mice had greatly reduced levels of IgE similar to wild-type controls. CD8
 
1
 
 
 
T cells played a rel-
atively small role as IgE responses were reduced to about the same extent in 
 
b
 
2
 
 microglobulin-
deficient, or in anti-CD8–treated wild-type mice as in normal mice after aerosol OVA treat-
 
ment. Similarly, T cell receptor (TCR)-
 
g
 
/
 
d
 
 T cells were not required for maximal inhibition of
the IgE response. These results demonstrate that exposure to inhaled protein antigens can in-
duce a state of unresponsiveness of CD4
 
1
 
 T cells that results in a prolonged loss of IgE and
eosinophil responses to subsequent challenges. This T cell unresponsiveness was shown not to
require CD8
 
1
 
 or TCR-
 
g
 
/
 
d
 
1
 
 T cells or IFN-
 
g
 
.
 
T
 
he respiratory tract is in constant contact with airborne
particles from the environment. Immune responses are
mounted to most inhaled pathogens but normally not to
abundant nonpathogenic antigens such as pollen and ani-
mal danders. This differential responsiveness is due, in part,
to a series of specific and nonspecific barriers including the
filtration in the nose, tight junctions between epithelial
cells, secretory antibodies, and pulmonary macrophages in
the lower respiratory tract (reviewed in reference 1). De-
spite the presence of these barriers, sensitization against
nonpathogenic antigens can occur, often with features of a
Th2 response (2).
Th2 responses are mediated by CD4
 
1
 
 
 
cells that secrete
cytokines such as IL-4, IL-5, IL-10, and IL-13 that are
known to play a central role in allergic responses (3–5). IL-4
(and IL-13 in humans) regulates the production of IgE (6–8)
and IL-5 is responsible for the growth, differentiation, and
activation of eosinophils (reviewed in reference 9). Ele-
vated levels of eosinophils are an indicator of allergy and
increased numbers correlate well with the severity of an al-
lergic asthmatic condition (10, 11). A second major subset
of T helper cells, designated Th1, secretes IL-2, TNF, and
IFN-
 
g
 
, mediates delayed-type hypersensitivity responses,
and is inhibitory for Th2 responses (12). IFN-
 
g
 
 is the Th1
cytokine responsible for the inhibition of IL-4–mediated
IgE responses both in vitro
 
 
 
and in vivo (13). More re-
cently, it was found that IFN-
 
g
 
 from CD8
 
1
 
 
 
cells may play
a role in the natural immune response to inhaled soluble
protein antigens (14). Exposure of naive rats to repeated
doses of aerosolized OVA induced MHC class I–restricted,
OVA-specific IFN-
 
g
 
–producing CD8
 
1
 
 T cells that could
suppress the IgE response to OVA. This suppression was
transferable with a small subset of antigen responsive
CD8
 
1
 
, TCR-
 
g
 
/
 
d
 
1
 
 T cells (15, 16).
This study was undertaken to analyze the effects of aero-
sol exposure of mice to OVA on subsequent immunogenic
  
722
 
Aerosol-induced IgE Unresponsiveness
 
challenges with this antigen. To directly address whether
IFN-
 
g
 
 and specific subsets of IFN-
 
g
 
 producing cells are re-
quired to confer a state of IgE unresponsiveness, in vivo ex-
periments were carried out using mice deficient in IFN-
 
g
 
,
CD8, and 
 
g
 
/
 
d
 
 cells. OVA-specific immunoglobulins, cyto-
kines, and blood eosinophils from these mice were com-
pared with wild-type controls.
 
Materials and Methods
 
Animals.
 
BALB/cAnN mice were obtained from Simonsen
Laboratories (Gilroy, CA) and Taconic Farms Inc. (Germantown,
NY). C57BL/6J mice and C57BL/6J-
 
Tcrd 
 
tm1 Mom 
 
were obtained
from The Jackson Laboratories (Bar Harbor, ME). BALB/c-Ifg
 
tm1
 
were obtained as heterozygotes and inbred to produce homozy-
gotes at DNAX. BALB/cAnN-
 
b
 
2
 
m
 
tm1Unc
 
 were derived from
BALB/cJ-
 
b
 
2
 
m
 
tm1Unc
 
 mice supplied by Dr. Derry Roopenian (The
Jackson Laboratories). These mice were backcrossed three times
onto the BALB/cAnN subline and inbred to produce homozy-
gous mutant mice. All animals were raised free of common
mouse pathogens condition at the DNAX Research Institute ani-
mal facility. They were 6–8 wk old at the start of each experi-
ment. Female mice were used for most experiments. However,
comparison within some experiments using both male and female
mice revealed no sex-related differences.
 
Aerosol and Intraperitoneal Antigen Exposure.
 
The first experi-
ment was a dose titration to determine the amount of inhaled
OVA necessary to cause maximal reduction in the OVA-specific
IgE response. Naive mice (5 mice/group) were exposed to differ-
ent concentrations of aerosolized OVA in PBS for 10 d (begin-
ning at day 0). Aerosolization was performed for 20 min using a
Passport aerosol compressor (Invacare Corporation, Elyria, OH)
connected to a box 3 ft
 
3
 
 in size that served as the deposition
chamber for the mice. Control mice were exposed to aerosolized
PBS from days 0 through 9. At day 27, all groups were challenged
intraperitoneally (IP)
 
1
 
 with 10 
 
m
 
g OVA (grade V, A-5503; Sigma
Chemical Co., St. Louis, MO) in 2 mg of aluminum hydroxide
(AL) gel (OVA/AL IP). On day 120 all mice were exposed to 1%
aerosolized OVA. For all other experiments, mice were typically
divided into three groups. In one group, mice were sensitized
with 10 
 
m
 
g OVA/AL IP. A second group was exposed to 1%
aerosolized OVA daily from day 0 to 9 while a third group was
exposed to aerosolized PBS. All groups received 10 
 
m
 
g OVA/AL
IP on day 21 and 1% aerosolized OVA for 20 min on day 35. For
experiments using TCR-
 
d2/2
 
 mice, OVA/AL IP challenge was
carried out on day 19 and the final exposure to 1% aerosolized
OVA was performed on day 44. Mice were bled from tail veins
and serum stored at 
 
2
 
70
 
8
 
C until assayed for antibody.
 
In Vivo Antibody Treatment.
 
Mice were injected intraperito-
neally with the monoclonal antibody 2.43 (0.5 mg/mouse) for
the depletion of CD8 cells. For depletion of CD4 cells, each
mouse was injected with 0.5 mg of GK 1.5. Isotype control anti-
body was GL113 that was given at 2 mg/mouse.
Mice were depleted of IFN-
 
g
 
 by injection of 1 mg of rat IgG
anti–mouse IFN-
 
g
 
 (XMG-1.2). This dose of anti–IFN-
 
g
 
 has
been shown to be effective in many experiments, and, in one in-
stance, was able to neutralize both endogenous IFN-
 
g
 
 and 150
 
m
 
g of recombinant IFN-
 
g
 
 over a 1-wk time course (17). The
anti-CD8 depletion was verified by flow cytometry of spleen cells
from mice treated 48 h earlier (not shown).
 
Quantification of Eosinophils in the Peripheral Blood.
 
Eosinophils
were quantified by dilution of heparinized blood in Discombe’s
fluid as previously described (18). This cell suspension was placed
on a hemacytometer and eosinophils counted with a light micro-
scope.
 
Cytokine ELISA.
 
Sandwich ELISAs were done to measure
IL-3, IL-5, IL-10, and IFN-
 
g
 
 as described by Abrams (19). In
brief, ELISA plates were coated with the appropriate anticytokine
antibodies and incubated at 4
 
8
 
C overnight. After incubation,
plates were blocked for 30 min at room temperature by adding
150 
 
m
 
l of 20% FCS PBS containing 0.04% Tween 20 (FCS-
PBST; Sigma Chemical Co.) to each well. Supernatants from in
vitro restimulations of lung cells were diluted in 5% FCS RPMI
and added to each well at a volume of 50 
 
m
 
l/well. Plates were in-
cubated overnight at 4
 
8
 
C then washed and the second-step anti-
body that was diluted in FCS-PBST was added at 50 
 
m
 
l/well.
Plates were incubated for 1 h then washed and the enzyme con-
jugate, diluted in FCS-PBST, was added to each well. Plates re-
mained at room temperature for 1 h after which they were
washed and 100 
 
m
 
l/well of substrate containing 1 mg/ml 2,2
 
9
 
-
azinobis(3-ethylbenzthiazolinesulfonic acid (Sigma Chemical Co.),
0.003% H
 
2
 
O
 
2
 
 in 0.1 M Na
 
2
 
HPO
 
4
 
,
 
 
 
and 0.05 M citric acid was
added. After the substrate was developed, the reaction was
stopped by applying 0.05 ml of 0.2 M citric acid solution to each
well. The plates were read on an ELISA reader (Molecular De-
vices Corp., Sunnyvale, CA) at wavelengths 
 
l
 
1
 
–
 
l
 
2, 
 
where 
 
l
 
1
 
equaled 405 and 
 
l
 
2
 
 was 490.
 
Analysis of OVA-specific Serum IgE.
 
OVA-specific serum IgE
was determined using a two-step sandwich ELISA as described by
van Halteren and colleagues (20). The coating antibody was a
monoclonal anti-IgE antibody called EM95. The second step was
a digoxigenin-coupled ovalbumin (DIG-OVA) that was prepared
from a kit containing digoxigenin-3-
 
O
 
-methylcarbonyl-
 
e
 
-amono-
caproic acid 
 
N
 
-hydroxy-succinimide ester (Boehringer Mannheim
GmbH, Mannheim, Germany). In brief, plates were coated with
2 
 
m
 
g/ml of EM95 and incubated overnight at 4
 
8
 
C. The serum
samples were added and subsequently the DIG-OVA was added
to the wells. Antidigoxigenin–Fab fragments coupled to peroxi-
dase (Boehringer Mannheim GmbH, Mannheim, Germany) was
added. After 1 h of incubation, 0.1 ml of substrate as described
above was added to each well.
 
Analysis of OVA-specific IgG1 and IgG2a.
 
ELISA plates were
coated overnight at 4
 
8
 
C with 10 
 
m
 
g/ml of OVA in PBS. The de-
tecting antibody for IgG1 that was used at 0.5 
 
m
 
g/ml, was a bioti-
nylated rabbit anti-IgG1 (21). The detecting antibody for the
IgG
 
2a 
 
was a rabbit anti-IgG2a coupled with the nitroiodophenyl
(NIP) hapten. After incubation and washing, peroxidase-conju-
gated streptavidin was added to the wells of the IgG1 ELISA. The
NIP-labeled anti-IgG2a
 
 
 
was reacted with a horseradish peroxidase
conjugate of a rat monoclonal anti-NIP antibody. Finally plates
were developed as described in (21). Standards for OVA-specific
IgG1 was pooled sera from hyperimmunized BALB/c mice. The
concentration of OVA-specific IgG1 was estimated by compari-
son to an IgG1 standard run in parallel on anti-IgG1–coated
plates. This method was also used for the quantification of OVA-
specific IgE and IgG2a in the ELISA.
 
In Vitro Restimulation of Lung Cells.
 
Mice were killed and
their lungs and associated lymph nodes removed aseptically, cut
into small pieces, and forced against a sterile No. 100 steel mesh
 
1
 
Abbreviations used in this paper:
 
 AL, aluminum hydroxide; 
 
b
 
2
 
m
 
2/2
 
, 
 
b
 
2
 
microglobulin knock-out mice; DIG, digoxigenin; IFN-
 
g2/2
 
, IFN-
 
g
 
gene knock-out mice; IP, intraperitoneally; NIP, nitroiodophenyl; T,
Tween 20; TCR-
 
d2/2
 
, T cell receptor 
 
d 
 
knock-out mice. 
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(Tylinter Inc., Mentor, OH) with the piston of a 10-ml plastic sy-
ringe. The suspended cells were washed three times in Hanks
BSS solution. The cells were stimulated in 1-ml cultures. The
culture medium consisted of RPMI 1640 (JRH Biosciences, Len-
exa, KS) with 10% heat-inactivated FCS (Sigma Chemical Co.),
0.05 mM 2-ME (Sigma Chemical Co.), 2 mM 
 
L-glutamine (JRH
Biosciences), and penicillin/streptomycin (GIBCO BRL, Gaith-
ersburg, MD). Lung cells were stimulated at 5 3 106 cells/ml in
culture medium containing 0.25 mg/ml OVA. The supernatant
was harvested at 72 h.
Measurement of OVA in the Lungs of Aerosolized Mice. Immedi-
ately after a single OVA exposure, lungs were removed and a cell
suspension was prepared as above. The supernatant from the cen-
trifugation was retained for quantification of OVA by an OVA-
specific ELISA. Plates were coated with 5 mg/ml of rabbit anti–
chicken egg albumin (Sigma Chemical Co.) in PBS and incu-
bated overnight. After incubation, plates were blocked by adding
FCS PBST. Plates were washed and samples were titrated on the
test wells and incubated for a minimum of 3 h. Plates were
washed and 1 mg/ml of biotin-labeled rabbit anti–chicken egg al-
bumin was added to each test well. After 1 h of incubation horse-
radish peroxidase–conjugated streptavidin was added to each
well. After incubation for 1 h, substrate was added and plates de-
veloped as described for antibody ELISA.
Analysis of IL-4. IL-4 from cultured supernatant was detected
by a bioassay using the IL-4–dependent CT.4S cell line (donated
by Dr. William Paul, National Institutes of Health, Bethesda,
MD). Cells were counted, washed, and resuspended in culture
medium at a concentration of 1 3 105 cells/ml of medium. Stan-
dard and supernatants to be tested were titered on to 96-well flat
bottom plates at 50 ml/well. The range of the standard was 100
pg/ml to 0.78 pg/ml. The culture medium containing the CT.4S
cells was added to the wells at a concentration of 50 ml per well.
Plates were incubated for 72 h at 378C in a humidified atmo-
sphere containing 5% CO2. At the end of the incubation period,
10 ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (Sigma Chemical Co.) was added to each well and the
plates were incubated for 4 h at 378C. After incubation, 150 ml of
0.04 N HCL in isopropanol was added to each well and the ab-
sorbance were measured from an ELISA reader at wavelengths
570 and 650.
Statistics. Levels of antibodies, eosinophils, and cytokines
were calculated as mean and SEM. The two-tailed P values were
calculated according to the Mann-Whitney test. A value of P ,0.05
was considered significant.
Results
OVA-specific IgE Antibodies Were Reduced but IgG1 and
IgG2a Were Elevated in Mice Sensitized with Aerosolized
OVA. A dose titration experiment was carried out to de-
termine the amount of inhaled OVA necessary to cause
maximal reduction in the OVA-specific IgE response. Na-
ive mice were exposed to various concentrations of aero-
solized OVA for 10 d, (beginning at day 0). At day 27, all
groups were challenged with an intraperitoneal injection of
10 mg OVA/AL, a challenge previously shown to elicit
strong primary and secondary IgE responses. OVA-specific
IgE responses were much lower in all groups exposed to
aerosolized OVA as compared with the control group ex-
posed to aerosolized PBS (Fig. 1). Maximal reduction of
Figure 1. IgE, IgG1, and IgG2a anti-OVA antibody production in
BALB/c mice after exposure to OVA. Naive BALB/c mice were primed
by exposing them to aerosolized OVA for 10 d, beginning at day 0. The
concentration of the OVA administered was 1%, 0.1%, 0.01%, 0.001%, or
PBS. At day 27, all groups were challenged with an intraperitoneal injec-
tion of 10 mg OVA/AL and on day 120, they were exposed to 1% aero-
solized OVA for 20 min. Mice were bled from their tail veins on day 50
and 131. OVA-specific antibodies were estimated by ELISA and ex-
pressed as mean 6 SEM.
the IgE response was observed in groups exposed to 1%
down to 0.01% OVA. There was a 30-fold decrease in
OVA-specific IgE in these groups when compared with
the PBS control group (P ,0.02). Partial reduction of IgE724 Aerosol-induced IgE Unresponsiveness
was observed with 0.001% OVA, the lowest concentration
tested. To determine the persistence of the IgE unrespon-
siveness, all mice were challenged again on day 120, this
time with 1% aerosolized OVA. The OVA-specific IgE re-
sponses in all aerosol exposure groups remained substan-
tially below the responses in the control group (Fig. 1).
To estimate the amounts of OVA actually delivered to
the lungs, naive mice were exposed to varying doses of
aerosolized OVA for 20 min and their lungs removed im-
mediately for assay of OVA. Mice given a 20-min aerosol
exposure to 1% OVA, the highest concentrations used in
these experiments, received a dose of 3.35 6 0.4 mg of
OVA to their lungs (Fig. 2). Each 10-fold reduction of
OVA concentration resulted in a z10-fold reduction in
the amount of OVA delivered to the lungs although the
OVA concentration in 0.001% OVA-treated mice was be-
low the threshold of detection in the ELISA. The clearance
of OVA from the lungs was rapid. Mice exposed to 1%
OVA cleared 86% of the antigen within 17 h and 99.5% by
48 h (data not shown).
The effects of the initial aerosol exposures on the OVA-
specific IgG1 and IgG2a responses to subsequent challenge
with OVA/AL IP differed markedly from the effects on the
IgE response (Fig. 1). Aerosol exposure led to a dose-
dependent priming for both isotypes and all doses tested
primed the mice for higher responses than the PBS control.
After the second challenge (Fig. 1 day 131) OVA-specific
IgG1 and IgG2a responses remained higher in all groups
previously exposed to aerosolized OVA but the priming
was less apparent, as even the PBS control group now rep-
resented a secondary antibody response. In summary, the
10-d course of aerosol exposure to a wide range of OVA
concentrations led to enhanced IgG1 and IgG2a responses
to subsequent immunogenic challenges with OVA, but si-
multaneously induced a profound and long lasting absence
of OVA-specific IgE responses to the same challenges.
These results demonstrated that primary exposure to an
aerosolized protein can lead to an unresponsiveness to sub-
sequent immunogenic challenge that is quite specific for
the IgE isotype. We have recently found that five aerosol
exposures, on alternate days, resulted in a comparable loss
of the OVA-specific IgE response (data not shown).
Depletion or Absence of CD81 T Cells Had a Minimal Effect
on IgE-specific Unresponsiveness. The IgE-specific suppres-
sion induced by aerosolized OVA that was described by
Holt and colleagues could be transferred by CD81 T cells
in both the rat (15) and the mouse (16). To determine
whether CD81 T cells were required for the response in
our studies, aerosol- and PBS-treated mice were depleted
of CD81 T cells by injection of anti-CD8, either during
the aerosol exposures (day 1 and 7) or just before the sec-
Figure 2. Measurement of OVA in the lung of BALB/c mice after 20
min of exposure to aerosolized OVA. Mice (5–10 mice per group) were
exposed to aerosolized OVA at concentrations from 1 to 0.001%. Lungs
were removed immediately, placed on a wire mesh, minced, and then
suspended in 10 ml of RPMI. Suspension was centrifuged and superna-
tant assayed by ELISA for OVA.
Table 1. OVA-specific IgE and IgG1 in BALB/c Mice After Depletion of CD4 or CD8 and Exposure to OVA
Antibody
administered (day) Primary exposure
IgE IgG1
Day 7 after 2° Day 7 after 3° Day 7 after 2° Day 7 after 3°
ng/ml mg/ml
GL113 (21,17) 1% Aerosolized OVA day 0–9 11 6 26  6  2 142 6 39 424 6 147
Anti-CD4 (21,17) 1% Aerosolized OVA day 0–9 ,1.56 ,1.56 ,0.23 ,0.23
Anti-CD8 (21,17) 1% Aerosolized OVA day 0–9 15 6 7 ,1.56 180 6 25 244 6 60
Anti-CD8 (20, 34) 1% Aerosolized OVA day 0–9 7 6 3 33 6 22 771 6 447 1,321 6 700
Anti-CD4 (21,17) PBS ,1.56 ,15.6 ,0.23 ,0.23
Anti-CD8 (21,17) PBS ,1.56 263 6 40 ,0.23 259 6 67
Anti-CD8 (20, 34) PBS ,1.56 244 6 60 ,0.23 192 6 36
GL113 (21,17) PBS ,1.56 169 6 61 ,0.23 383 6 73
2° 10 mg OVA/AL IP on day 21. 3° 1% Aerosolized OVA on day 35.725 Seymour et al.
ondary and tertiary OVA challenges (day 20 and 34). For
this, and all subsequent experiments, a standardized sched-
ule of aerosol exposure on days 0 through 9, followed by
intraperitoneal challenge with OVA/AL on day 21 and a
single aerosol OVA challenge on day 35 was used (see Ta-
ble 2).
Administration of anti-CD8 on day 1 and day 7 did not
prevent aerosol OVA–induced IgE unresponsiveness (Ta-
ble 1), after the secondary challenge (15 6 7 compared
with 11 6 2 ng/ml anti-CD8 and control antibody, re-
spectively). The slightly higher IgE response in anti-CD8–
treated mice was transient as there was no elevation of
OVA-specific IgE when these mice were reexposed to
aerosolized OVA. However, in vivo depletion of CD8 cells
in the PBS control groups led to a slight enhancement of
the OVA-specific IgE response. To determine the impor-
tance of CD8 T cells after the IgE unresponsiveness was es-
tablished, mice were treated with anti-CD8 1 d before
both the 28 and 38 OVA exposures. The OVA-specific IgE
of these mice was slightly higher than other aerosol-treated
groups, but was still significantly lower than the PBS ex-
posed, control antibody-treated group (33 6 22 compared
with 169 6 61, P 5 0.05, n 5 5). As expected, treatment
of mice with anti-CD4 resulted in the ablation of both the
OVA-specific IgE and IgG1 responses.
To confirm that the OVA-specific IgE unresponsiveness
in anti-CD8–treated, aerosol OVA–exposed mice was not
due to small numbers of residual CD81 T cells, experi-
ments were carried out using BALB/c mice that lacked
CD8 T cell due to the disruption of the b2m gene. In these
experiments, an additional control group of mice injected
with 10 mg OVA/AL IP at day 0 was added. All groups re-
ceived a secondary challenge of OVA/AL IP on day 21 and
a tertiary challenge of 1% aerosolized OVA on day 35.
BALB/c  b2m2/2 mice exposed to aerosolized OVA had a
sevenfold reduction in OVA-specific IgE when compared
with the PBS control b2m2/2 group (14 610 vs. 96 6
25, respectively, Table 2). However, in most experiments,
the reduction in IgE responses was not quite as complete in
b2m2/2 mice as in the aerosolized OVA-treated wild-
type group (14 610 vs. 6 6 2, respectively) at day 7 after
the 38 challenge. Comparison of IgG1 responses between
aerosol OVA– and OVA/AL IP–primed mice shows that
aerosol priming, although significant, was not as effective as
priming by OVA/AL injection. In summary, CD81 T cells
did not appear to be required for the loss of IgE responsive-
ness after aerosol OVA exposure.
IFN-g Was Not Required for Aerosol OVA–induced IgE
Unresponsiveness. IFN-g produced either by CD81 T cells
or CD41 Th1 cells has the potential to preferentially in-
hibit IgE responses. To determine whether IFN-g was in-
volved in OVA-specific IgE unresponsiveness in mice ex-
posed to aerosolized OVA, experiments were done with
BALB/c IFN-g2/2 mice (Table 2). The experimental
protocol was as described for the b2m2/2 mice. IgE-spe-
cific unresponsiveness after aerosolization was as complete
in IFN-g2/2 as in wild-type controls. The OVA-specific
IgE responses in control groups were similar to those in
wild-type mice, but IgG1 responses were generally higher
in IFN-g2/2 mice. In similar experiments, anti–IFN-g
antibody treatment of aerosol OVA primed BALB/c mice
had no effect on the IgE unresponsiveness (data not
shown). These results demonstrated that the specific loss of
IgE responses was independent of IFN-g and suggested
that the aerosol exposure to OVA did not induce a domi-
nant Th1-like response.
TCR-g/d T Cells Were Not Required for Aerosol OVA–induced
IgE Unresponsiveness. It has been reported that T cells bear-
ing TCR-g/d are the principal mediators of transferable
IgE-specific suppression to OVA in mice (16) and rats (15).
To try to confirm this, TCR-d2/2 and wild-type mice
were primed with aerosolized OVA or PBS or OVA/AL
Table 2. OVA-specific IgE and IgG1 in Wild-type, b2m2/2 and IFN-g2/2 Mice After Exposure to OVA
Mice Primary exposure
IgE IgG1
Day 7 after 2° Day 7 after 3° Day 7 after 2° Day 7 after 3°
ng/ml mg/ml
IFN-g2/2 1% Aerosolized OVA day 0–9 7 6 3 ,1.56 120 6 34 249 6 99
b2M2/2 1% Aerosolized OVA day 0–9 14 6 9 14 6 10 317 6 241 187 6 102
Wild-type 1% Aerosolized OVA day 0–9 11 6 56  6  2 142 6 39 424 6 147
IFN-g2/2 PBS ,1.56 166 6 52 ,0.23 82 6 19
b2M2/2 PBS ,1.56 96 6 25 ,0.23 84 6 39
Wild-type PBS ,1.56 169 6 61 ,0.23 383 6 73
IFN-g2/2 10 mg OVA/AL IP day 0 516 6 61 555 6 264 3,073 6 705 10,122 6 1607
b2M2/2 10 mg OVA/AL IP day 0 337 6 63 417 6 73 2,768 6 1466 2,077 6 338
Wild-type 10 mg OVA/AL IP day 0 379 6 100 446 6 150 4,141 6 2216 3,351 6 554
2° 10 mg OVA/AL IP on day 21. 3° 1% Aerosolized OVA on day 35.726 Aerosol-induced IgE Unresponsiveness
IP and rechallenged twice, as in previous experiments. The
ability of aerosol OVA priming to induce subsequent IgE
unresponsiveness to OVA was not impaired in mice with
no TCR-g/d T cells. Indeed, the deletion of this popula-
tion had no significant effect on the tertiary (Table 3) or
secondary (not shown) IgE or IgG1 responses with any of
the priming conditions. The threefold difference in IgG1
responses in the PBS primed groups in the experiment
shown in Table 3 was not a consistent finding.
Blood Eosinophilia Was Reduced in Aerosolized OVA-sensi-
tized Mice. To determine whether the eosinophil re-
sponse that usually accompanies a strong Th2 response was
also reduced in mice initially exposed to aerosolized OVA,
eosinophils were counted at day 4 after the 38 challenge of
BALB/c  b2m2/2, IFN-g2/2, and wild-type controls.
Blood eosinophil numbers were quite elevated in all groups
of animals primed with OVA/AL IP or aerosolized PBS
(Fig. 3). In wild-type, IFNg2/2, and b2m2/2 mice ren-
dered unresponsive with aerosol OVA, however, eosino-
phils were not significantly elevated, as compared with un-
immunized mice of the same genotype. Indeed, the slight
elevation of eosinophils in some of the IgE unresponsive
groups over the unexposed controls may be due to the
presence of alum from the IP injection as there was no ele-
vation in groups after the initial 10-d exposure to aero-
solized OVA (data not shown). Injection of alum alone
into naive mice can cause elevation of blood eosinophils
(unpublished observation). Thus, mice primed by aero-
solized OVA are deficient in eosinophil responses, as well
as IgE responses.
Cytokine Profiles in the Lungs of Mice After Allergen Sensiti-
zation. To determine whether Th2 responses were re-
duced and/or Th1 responses induced in aerosol OVA-
exposed mice, cytokine production was measured after the
38 exposure to aerosolized OVA. Time course experiments
have shown that the peak cytokine recall response from
lung cells in vitro occurred 5–8 d after OVA/AL-sensitized
mice are exposed to aerosolized OVA (22). For these ex-
periments, lungs were removed and restimulated in vitro
on day 7 after the 38 exposure. Pooled cells from the ho-
mogenized lungs and associated lymph nodes were used for
in vitro restimulation. We have seen no substantial differ-
ences in the cytokine response in the lungs when compared
with the associated lymph nodes (our unpublished observa-
Table 3. IgE and IgG1 Anti-OVA Response in Wild-type and TCR-d2/2 Mice After Exposure to OVA
Mice Primary exposure IgE Day 7 after 3° IgG1 Day 7 after 3°
ng/ml mg/ml
Wild-type 1% Aerosolized OVA day 0–9 15 6 8 142 6 61
TCR-d2/2 1% Aerosolized OVA day 0–9 5 6 0.5 310 6 213
Wild-type PBS 188 6 132 233 6 65
TCR-d2/2 PBS 144 6 73 694 6 153
Wild-type 10 mg OVA/AL, day 0 600 6 275 1,268 6 413
TCR-d2/2 10 mg OVA/AL, day 0 713 6 412 1,283 6 419
2° 10 mg OVA/AL IP on day 19. 3° 1% Aerosolized OVA on day 44.
Figure 3. Blood eosinophils in OVA-sensi-
tized mice. h, Wild-type,  , b2m2/2, and j,
IFN-g2/2 BALB/c mice were bled from the
tail vein on day 4 after the tertiary exposure and
the eosinophils were counted in Discombe’s
fluid on a hemacytometer (18). Data represent
the mean (6 SEM) eosinophil counts per milli-
liter in groups of five mice.727 Seymour et al.
tion). Mice primed by OVA/AL IP or PBS mounted a
strong Th2 response as indicated by the significant levels of
IL-4, IL-5, and IL-10 and undetectable levels of IFN-g
(Table 4). IFN-g–, and b2m-deficient mice from the PBS
control group made similarly elevated levels of IL-4, IL-5,
and IL-10 (data not shown). Cytokines were generally
even higher in control mice that received both primary and
secondary immunizations with OVA/AL IP. In contrast,
Th2 cytokines were not detected in mice primed by passive
inhalation of OVA except for very low levels of IL-4. Fur-
thermore, IFN-g was not detected in any of the aerosol
OVA–treated groups. A similar pattern of cytokine re-
sponse was observed from restimulated spleen cells. Spleens
from the PBS control group that received subsequent chal-
lenges with OVA/AL IP made a strong Th2 cytokine re-
sponse whereas those primed by repeated exposure to aero-
solized OVA remained virtually unresponsive (unpublished
observation). Thus, aerosol-sensitized mice showed no evi-
dence of preferential induction of a Th1 response to OVA,
rather the T helper response in these mice was largely ab-
sent in comparison to the control groups.
Discussion
The nature of the initial CD41 T cell response to an air-
borne antigen is central in determining whether or not an
allergic response is made to subsequent exposures to the
same antigen. However, relatively few studies have investi-
gated the nature of the primary T cell response to aero-
solized protein antigens. Substantially more is known about
the allergic responses to aerosol antigens in experimental
animals primed initially for a Th2 response by an intraperi-
toneal or subcutaneous route. In this study, the IgE, eosi-
nophil, and CD41 T cell responses of mice primed by ex-
posure to repeated doses of aerosolized OVA were compared
with optimally Th2-primed and unprimed mice. We have
confirmed the observations of Holt and coworkers (14, 23)
that animals repeatedly exposed to low levels of aerosolized
OVA are unable to produce IgE antibodies to subsequent
immunogenic challenges to OVA, but produce normal sec-
ondary IgG responses to such challenges. However, the re-
sults of investigation into the nature of the Th response that
accompanies this isotype-specific unresponsiveness have led
us to somewhat different conclusions about the mechanism
of this isotype-specific unresponsiveness.
Intraperitoneal injection of 10 mg OVA/AL induced
OVA-specific IgE in naive BALB/c mice, but not in mice
exposed previously for 10 d to aerosolized OVA. This IgE
unresponsiveness was induced, in a dose-dependent man-
ner, by a wide range of aerosol OVA concentrations
(0.001–1%). These same doses did not suppress OVA-spe-
cific IgG1 and IgG2a responses, but rather primed them,
again in a dose-dependent manner. Thus, mice primed
with 1% OVA made the highest amount of OVA-specific
IgG1 and IgG2a and the lowest amount of OVA-specific
IgE response after the IP challenge. Moreover, the IgE-
specific unresponsiveness persisted with subsequent OVA
challenges, either single aerosol exposures or OVA/AL IP
injections (data not shown), and was observed as late as four
months after the initial aerosol exposures.
The actual doses of OVA delivered to the respiratory
tract were estimated by measuring the amounts of OVA re-
coverable in soluble form at the end of the exposure pe-
riod. They varied proportionally with the concentrations of
OVA used, from 3.5 mg to ,1.6 ng/dose. The most con-
sistent and complete inhibition of IgE responses was ob-
tained with the 3.5-mg dose and this was chosen for subse-
quent studies. This dose would not be expected to give
either the high dose or low dose tolerance seen in many
classical studies of immunological tolerance in mice (24–
26). Indeed, others have shown that 1–10 mg OVA given
intraperitoneally every other day, without adjuvant, for
10–14 d produces a strong Th2 response with high levels of
OVA-specific IgE (27).
Similar experiments have been performed to study regu-
lation of the immune response to aerosol antigens in inbred
Table 4. Cytokine Production After In Vitro Restimulation of Lung Cells from Aerosol-exposed Wild-type, b2m2/2
and IFN-g2/2 BALB/c Mice
Mice Primary exposure IL-3 IL-4 IL-5 IL-10 IFN-g
ng/ml pg/ml ng/ml U/ml ng/ml
b2M2/2 1% Aerosolized OVA day 0–9 ,0.156 21 6 1.9 ,0.156 ,0.625 ,0.156
IFN-g2/2 1% Aerosolized OVA day 0–9 ,0.156 21 6 2.0 ,0.156 ,0.625 ,0.156
Wild-type 1% Aerosolized OVA day 0–9 ,0.156 23 6 2.4 ,0.156 ,0.625 ,0.156
Wild-type PBS ,0.156 135 6 37 3.52 6 0.73 8.80 6 2.60 ,0.156
b2M2/2 10 mg OVA/AL IP day 0 ,0.156 425 6 82 12.90 6 1.1 34.10 6 5.4 ,0.156
IFN-g2/2 10 mg OVA/AL IP day 0 ,0.156 119 6 24 5.22 6 1.27 8.00 6 2.98 ,0.156
Wild-type 10 mg OVA/AL IP day 0 ,0.156 583 6 240 10.08 6 2.6 18.30 6 4.2 ,0.156
2° 10 mg OVA/AL IP on day 22. 3° 1% Aerosolized OVA on day 36. Restimulation was performed on day 7 after 3° in vivo antigen rechallenged
using 5 3 106 unseparated lung cells/ml plus 0.25 mg/ml OVA.728 Aerosol-induced IgE Unresponsiveness
rats (28–29). In those studies genetic factors influenced the
induction of IgE and IgG1 responses in different strains of
rats repeatedly exposed to aerosolized OVA. Low IgE re-
sponder WAG rats made very reduced levels of IgE and
IgG1 after repeated exposure to low doses of aerosolized
OVA (0.0001–1%) followed by subsequent intraperitoneal
injection of OVA/AL. In high IgE responder BN rats,
however, IgG1 responses were not suppressed and at least
1,000-fold greater doses of aerosolized OVA were required
for IgE-specific suppression. In this study, both BALB/c
and C57BL6 mice gave comparable IgE-specific unrespon-
siveness with 1% aerosolized OVA, but the dose titration
was performed only on BALB/c mice. It is possible that the
dose responses may be different among strains of mice.
The possible role of CD81 cells in the reduced IgE re-
sponses seen in mice exposed to repeated doses of aero-
solized OVA was tested in two ways. Depletion of CD81 T
cells with anti-CD8 antibody either during the aerosol sen-
sitization or during the secondary and tertiary challenges
had very little effect on the degree of inhibition of the IgE
response. This result was confirmed with b2m-deficient
mice that lack CD81 T cells. In most experiments, aerosol
OVA–treated BALB/c b2m2/2 mice did not make IgE
responses higher than wild-type controls. In a minority of
experiments, the inhibition of IgE was not as complete in
the b2m2/2 mice, but was well below the levels in PBS-
treated control mice. In PBS and OVA/AL IP controls,
BALB/c b2m2/2 mice gave IgE responses that were not
significantly different from those in wild-type mice. Thus,
it appears that CD81 T cells do not have a major role in
aerosol-induced IgE unresponsiveness to soluble protein
antigens. In contrast, Holt and coworkers have shown that
as few as 1 3 106 CD81 T cells from aerosol OVA sensi-
tized mice could adoptively transfer an active IgE-specific
suppression in both rats (15) and mice (16) challenged with
OVA/AL IP. Similarly, it has been shown that cells from
OVA-exposed mice reconstituted with OVA–sensitized
CD81 T cells, made reduced levels of IgE and IgG1 re-
sponses when stimulated in vitro (30). It should be noted
that our experiments do not rule out the possibility that
CD81 T cells could transfer an IgE-specific suppression,
but simply show that such suppression does not require
CD81 T cells in the primary host.
Likewise it has been suggested that TCR-g/d1 T cells
are the principal mediators of IgE-specific suppression in
this model. In adoptive transfer experiments, as few as 3 3
104 TCR-g/d1 cells from aerosol OVA–primed mice sup-
pressed OVA-specific IgE from mice primed by OVA/
AL(16). Our finding that mice deficient in TCR-g/d1 T
cells have the same degree of IgE-specific unresponsiveness
as wild-type controls after aerosol priming and intraperito-
neal challenge with OVA argues that such cells are not re-
quired for this unresponsiveness. Again, our results do not
preclude that TCR-g/d1 T cells can also mediate this un-
responsiveness.
A reasonable hypothesis to explain the highly specific in-
hibition of the production of IgE, but no other isotype
would be that repeated aerosol exposure induced Th1-
biased T cell response and that IFN-g was the specific in-
hibitor of IgE production. Th1 cells in vitro can provide
help for all Ig isotypes except IgE (13). In vivo, there are
many demonstrations of the IgE inhibitory effects of IFN-g
(31–33), and the ability of Th1 responses to suppress IgE
production (34–36). However, the results presented here
make clear that IFN-g is not required for maximum IgE
unresponsiveness, either during the initial aerosol sensitiza-
tion or during subsequent immunogenic challenges. Mice
rendered either temporarily deficient in IFN-g by treat-
ment with a neutralizing antibody, or congenitally deficient
by disruption of the IFN-g gene, developed quite normal
IgE responses in control groups and developed IgE unre-
sponsiveness identical to control mice when exposed to
aerosolized OVA. Furthermore preliminary studies show
that treatment of mice with neutralizing antibodies to IL-
12, a cytokine required for optimum production of IFN-g
(37), was also ineffective in preventing this state of IgE-spe-
cific unresponsiveness (data not shown).
Direct examination of the OVA-specific T cell recall re-
sponse in vitro revealed that aerosol OVA–primed mice did
not develop significant CD41 T cell responses of either a
Th1 or Th2 type in the lungs, after subsequent challenges
with OVA under conditions that stimulate strong, highly
polarized Th2 responses in control groups. Thus it appears
that specific loss of IgE responses in aerosol OVA tolerized
mice reflects a more fundamental unresponsiveness in the
entire OVA-specific CD41 T cell population. Whether
this T cell unresponsiveness is intrinsic to the OVA-specific
T cells or reflects the action of a separate regulatory popu-
lation, has not yet been determined by us. However, previ-
ous experiments with this model in both rats and mice sug-
gest that an active suppression is involved (15, 16).
Although this low dose, aerosol-induced IgE and Th2
unresponsiveness is not due to preferential induction of an
OVA-specific Th1 response, a Th1 can lead to a pattern of
unresponsiveness similar to that described here. Using sev-
eral high (100 mg) intranasal doses of OVA to induce toler-
ance, van Halteren et al. (38) have shown induction of a
Th1-like response to OVA that inhibited subsequent IgE
responses via IFN-g. This unresponsiveness was specific to
IgE and could be transferred with CD41 T cells. Similar re-
sults were observed by Hoyne et al. (39) when mice were
given three intranasal doses (100 mg each) of peptides de-
rived from house dust mite allergen. Before the develop-
ment of tolerance, there was a rapid and transient activation
of CD41 T cells that secreted Th1 cytokines when restim-
ulated in vitro.
Similar analyses have been done to study the unrespon-
siveness that occurs after oral antigen ingestion. Although
some investigators have suggested that g/d (40) T cells reg-
ulate the induction of oral tolerance others have shown that
CD41 T cells are required for its induction (41–42). Inves-
tigators have shown that the feeding of mice transgenic for
OVA-specific TCR with high doses of OVA can inhibit
airway eosinophilic inflammation induced by intratrache-729 Seymour et al.
ally administered OVA. This inhibitory effect can be adop-
tively transferred by splenic CD41 T cells demonstrating
that it is an active mechanism. The suppression of eosino-
phils can also be blocked by anti–TGF-b but not by anti–
IFN-g (43). Marth and colleagues have shown that when
OVA-specific TCR transgenic mice were fed high doses of
OVA, it led to the generation of T cells from Peyer’s
patches that produced substantial amounts of IFN-g that
resulted in systemic unresponsiveness. However, adminis-
tration of anti–IL-12 to these animals led to an increase in
TGF-b. These investigators later postulated that low dose
oral tolerance may result from insufficient Th1 cytokines
but increase production of TGF-b (44, 45).Thus, a similar
mechanism may be occurring in this study. Therefore, if
this is an active suppression, mediated by CD41 T cells, it
may reflect similar activity of TGF-b–secreting CD41 T
cells (termed Th3; reference 46) or a CD41 regulatory T
cell subset similar to that recently described by Groux and
colleagues (47).
Consistent with the absence of a significant Th2 re-
sponse, primary exposure to aerosolized OVA also led to an
almost complete lack of an eosinophil response to subse-
quent OVA challenges. Blood eosinophils were signifi-
cantly elevated after challenges in PBS- and OVA/AL-
primed mice where aerosol OVA–primed mice showed
only slight enhancement of eosinophils. IFN-g has been
shown to regulate antigen-induced eosinophils in the air-
way of OVA/AL-sensitized mice (48) and it has also been
shown that depletion of CD81 T cells enhances pulmonary
inflammation (49). In this study, a threefold elevation in
circulating blood eosinophils was observed in unprimed
IFN-g2/2 and b2m2/2 mice when compared with the
wild-type controls. However, significant enhancement in
blood eosinophilia was seen only in the PBS- and OVA/
AL-primed mice. This absence of significant blood eosino-
philia in aerosol OVA–primed mice confirmed the absence
of a detectable IL-5 response.
In summary, the data presented above demonstrate a po-
tentially important mechanism that limits the induction of
Th2-mediated allergic responses to frequently encountered
airborne antigens. Although IFN-g, TCR-g/d1, and CD81
T cells have been suggested by others to be important parts
of the IgE-specific unresponsiveness, our results suggest a
loss of both Th1 and Th2 CD41 T cell responses occurs
that is not mediated by TCR-g/d1, CD81, cells or IFN-g.
Much about the mechanisms for regulation of a host re-
sponse to inhaled antigens remains to be defined. A knowl-
edge of this mechanism will help us understand the disreg-
ulation of the immune response that ultimately results in
pulmonary allergic disorders.
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